Details of the Drug-Related molecule(s) Interaction Atlas

VOROZOLE Drug Info

Vorozole; Rivizor; 129731-10-8; R-83842; UNII-1E2S9YXV2A; 1E2S9YXV2A; Vorozol [INN-Spanish]; Vorozolum [INN-Latin]; (+)-Vorozole; CCRIS 7482; Vorozolum; Vorozol; Rivizor (TN); 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole; Vorozole (USAN/INN); AC1OCF4T; (S)-VOROZOLE; SCHEMBL4554; Vorozole [USAN:INN:BAN]; CHEMBL224060; DTXSID20156230; (+)-(S)-6-(p-Chloro-alpha-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole; CHEBI:135387; 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl

Cross-matching ID

PubChem CID

6918191

ChEBI ID

CHEBI:135387

CAS Number

CAS 129731-10-8

TTD Drug ID

DM32N5G

General Information of Drug (ID: DM32N5G)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[3]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[4]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[4]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[5]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[6]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[7]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[9]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[10]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Adenylate kinase isoenzyme 1 (AK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[2]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[2]
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[2]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[2]
Selenium	DM25CGV	N. A.	N. A.	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[13]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[14]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[14]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adenylate kinase isoenzyme 1 (AK1)	OT614AR3	KAD1_HUMAN	Drug Response	[2]

------------------------------------------------------------------------------------

References

1	Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38.
2	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
3	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
4	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
5	Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
6	Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
7	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
8	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
9	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
11	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
12	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
13	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
14	Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
15	Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.